Hepatitis C Information - Peregrine Pharmaceutical Will Deliver Hepatitus C Phase I Safety Data

Peregrine Pharmaceutical Will Deliver Hepatitus C Phase I Safety Data
Medical News Today - Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for viral diseases and cancer, today announced that it has completed planned patient enrollment and dosing

Clinical Trial Results Show That Peregrine's First-In-Class Anti-Viral
Medical News Today - Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for viral diseases and cancer, today announced that it will present top line data demonstrating that its first-in

CROI: Rapid response predicts success in HIV/HCV coinfected patients
Aidsmap - Virological response to hepatitis C therapy after four weeks appears to predict who will have a successful response to a full course of treatment in HIV-positive people coinfected with hepatitis C genotypes 1 or 3, according to findings from two

Pharmacy Benefit
Managed Healthcare Executive - HEPATITIS B AND C are serious viral diseases that can lead to lifelong infection, cirrhosis, liver cancer, liver failure and death. They often produce chronic, hidden infections. An estimated 1.25 million Americans are infected with hepatitis B, and